Search
Close this search box.

How leukaemia inhibitory factor targets metastasis-initiating cancer stem cells in gastric cancer: insights from Cell Death Discovery

Leukaemia inhibitory factor (LIF) is a cytokine that has been found to play a crucial role in targeting metastasis-initiating cancer stem cells in gastric cancer. A recent study published in Cell Death Discovery has shed light on the mechanisms by which LIF inhibits the spread of cancer cells in the stomach, offering new insights into potential therapeutic strategies for this deadly disease.

Gastric cancer is one of the most common and aggressive forms of cancer, with a high mortality rate due to its propensity to metastasize to other organs. Metastasis is the process by which cancer cells spread from the primary tumor to distant sites in the body, leading to the formation of secondary tumors. Cancer stem cells, also known as tumor-initiating cells, are a subpopulation of cells within a tumor that have the ability to self-renew and differentiate into various cell types, driving tumor growth and metastasis.

In the study, researchers investigated the role of LIF in targeting metastasis-initiating cancer stem cells in gastric cancer. They found that LIF treatment significantly reduced the number and size of tumor spheres formed by cancer stem cells in vitro, indicating that LIF inhibits the self-renewal and proliferation of these cells. Furthermore, LIF treatment suppressed the expression of stem cell markers and genes associated with metastasis in gastric cancer cells, suggesting that LIF may inhibit the ability of cancer stem cells to initiate metastasis.

The researchers also discovered that LIF exerts its anti-metastatic effects through the activation of the JAK/STAT signaling pathway, which plays a key role in regulating cell growth, survival, and differentiation. By activating this pathway, LIF inhibits the expression of genes involved in promoting metastasis and induces cell death in cancer stem cells, thereby preventing their spread to other organs.

These findings have important implications for the development of novel therapeutic strategies for gastric cancer. Targeting cancer stem cells is crucial for preventing tumor recurrence and metastasis, as these cells are often resistant to conventional chemotherapy and radiation therapy. By understanding how LIF targets metastasis-initiating cancer stem cells, researchers may be able to develop new drugs that specifically target these cells, leading to more effective and personalized treatments for patients with gastric cancer.

Overall, the study published in Cell Death Discovery provides valuable insights into the mechanisms by which LIF inhibits metastasis-initiating cancer stem cells in gastric cancer. Further research is needed to validate these findings in preclinical and clinical studies, but the potential therapeutic implications of targeting LIF signaling in gastric cancer are promising. By unraveling the complex interplay between cytokines, signaling pathways, and cancer stem cells, researchers are paving the way for more effective and targeted therapies for this deadly disease.